- Obesity program continues to progress, with first participants dosed in Phase 2 EMBRAZE trial of apitegromab in obesity CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback